The Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 376 participants.

Also called NCT04912167

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 376 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04912167
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04912167. Randomized; single masking; primary purpose treatment. Start 2021-11 (anticipated); primary completion 2022-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction
Acronym
PERI-STEMI
Condition
STEMI
Intervention (Drug)
Sacubitril-Valsartan
Intervention (Drug)
Enalapril
Intervention (Drug)
Valsartan
Lead sponsor
West China Hospital (class: other)

Record details

Record id
cardio:ct-nct04912167
Content hash
a3334b7001bf7b9ed0ccb9d5c6239775680153db47f41868b2ec8e34891b17d1